Quanterix Co. (NASDAQ:QTRX) Shares Sold by Emerald Mutual Fund Advisers Trust

Emerald Mutual Fund Advisers Trust lowered its holdings in Quanterix Co. (NASDAQ:QTRX) by 61.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 216,860 shares of the company’s stock after selling 346,387 shares during the quarter. Emerald Mutual Fund Advisers Trust owned 0.56% of Quanterix worth $2,305,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the business. Portolan Capital Management LLC lifted its holdings in shares of Quanterix by 2.7% in the 4th quarter. Portolan Capital Management LLC now owns 2,587,824 shares of the company’s stock valued at $27,509,000 after buying an additional 67,138 shares during the period. Vanguard Group Inc. lifted its holdings in Quanterix by 0.9% during the fourth quarter. Vanguard Group Inc. now owns 2,217,225 shares of the company’s stock valued at $23,569,000 after purchasing an additional 19,386 shares in the last quarter. William Blair Investment Management LLC acquired a new position in shares of Quanterix during the 4th quarter worth about $11,290,000. Easterly Investment Partners LLC lifted its stake in Quanterix by 9.0% in the 4th quarter. Easterly Investment Partners LLC now owns 954,995 shares of the company’s stock valued at $10,152,000 after buying an additional 78,862 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its holdings in Quanterix by 0.7% in the 4th quarter. Dimensional Fund Advisors LP now owns 893,645 shares of the company’s stock worth $9,500,000 after buying an additional 6,099 shares during the last quarter. Hedge funds and other institutional investors own 86.48% of the company’s stock.

Quanterix Stock Performance

Shares of QTRX stock opened at $5.78 on Tuesday. Quanterix Co. has a one year low of $4.67 and a one year high of $19.18. The firm’s 50 day moving average price is $6.50 and its 200-day moving average price is $9.48. The firm has a market cap of $224.20 million, a P/E ratio of -5.45 and a beta of 1.35.

Quanterix (NASDAQ:QTRX) last posted its quarterly earnings data on Monday, March 17th. The company reported ($0.30) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.03). The company had revenue of $35.16 million for the quarter, compared to analysts’ expectations of $34.93 million. Quanterix had a negative return on equity of 11.74% and a negative net margin of 30.12%. As a group, research analysts predict that Quanterix Co. will post -0.98 EPS for the current fiscal year.

Analysts Set New Price Targets

QTRX has been the subject of a number of research reports. Canaccord Genuity Group dropped their target price on shares of Quanterix from $20.00 to $15.00 and set a “buy” rating for the company in a report on Tuesday, March 18th. Scotiabank reaffirmed an “outperform” rating on shares of Quanterix in a research note on Tuesday, March 25th.

About Quanterix

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.